Search results
Gene Panel Predicts Early HER2+ Breast Cancer Prognosis
Medscape· 18 hours agoPatients with early-stage HER2+ breast cancer could soon be offered less intensive treatment based...
How Clorox Employees are Prioritizing Preventive Care
Morningstar· 5 days agoAs part of our ongoing commitment to our teammates' health and well-being, we put in place an educational campaign to increase use of preventive care screenings and track our progress against ...
Cancer death rates are dropping, but not for everyone
Scripps News via AOL· 5 days agoBlack women are two times more likely than white women to be diagnosed highly aggressive triple-...
Newly identified biomarkers may warn of cancer 7 years before symptoms set in
MedicalNewsToday via AOL· 3 days agoResearchers are investigating the potential of a set of blood biomarkers in predicting the risk of...
IRE1α determines ferroptosis sensitivity through regulation of glutathione synthesis - Nature...
Nature· 6 days agoThe endoplasmic reticulum (ER) is a major site of lipid peroxidation during ferroptosis. Here authors show that the ER protein IRE1α determines ferroptosis induction via regulating glutathione synthesis independent of the unfolded protein response.
ABVC BioPharma (NASDAQ:ABVC) Issues Earnings Results
ETF DAILY NEWS· 16 hours agoABVC BioPharma (NASDAQ:ABVC – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.40) earnings per share for the quarter, reports. ABVC BioPharma had ...
Earnings call: BioAtla reports promising data in cancer drug trials By Investing.com
Investing.com· 5 days agoBioAtla, a biotechnology company, has announced its first-quarter financial results and provided a...
Earnings call: GeoVax reports progress on key vaccine trials By Investing.com
Investing.com· 5 days agoGeoVax, a biotechnology company focusing on developing vaccines for cancer and infectious diseases,...
Robert W. Baird Cuts Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Price Target to $2.00
ETF DAILY NEWS· 2 days agoCalidi Biotherapeutics (NYSEAMERICAN:CLDI – Free Report) had its price objective decreased by Robert W. Baird from $4.50 to $2.00 in a research note published on Wednesday morning, Benzinga ...
Calidi Biotherapeutics (NYSEAMERICAN:CLDI) PT Lowered to $2.00 at Robert W. Baird
ETF DAILY NEWS· 2 days agoCalidi Biotherapeutics (NYSEAMERICAN:CLDI – Free Report) had its price target reduced by Robert W. Baird from $4.50 to $2.00 in a report released on Wednesday, Benzinga reports. Robert W. Baird ...
